secwatch.observer — SEC 8-K summary
======================================

Issuer:     CASTLE BIOSCIENCES INC (CSTL)
CIK:        0001447362
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001447362-22-000010
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Castle Biosciences expects FY 2021 revenue to meet or exceed $89-93M guidance; test volumes up 55%
--------------------------------------------------------------------------------

- FY2021 revenue expected at or above guided $89-93M; year-end cash ~$330M.
- Total gene expression profile test reports delivered in 2021: 28,118 (+55% YoY).
- DecisionDx-Melanoma reports up 25% YoY to 20,328 despite 11% drop in melanoma diagnoses vs pre-COVID.
- DecisionDx-SCC reports grew to 3,510 in 2021 from 485 in 2020; Q4 2021: 1,265 (+196%).
- myPath/DecisionDx DiffDx-Melanoma reports: 2,662 in 2021 vs 73 in 2020; Q4: 904 vs 73.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000010/0001447362-22-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447362/000144736222000010/cstl-20220110.htm
  HTML page:      https://secwatch.observer/filing/0001447362-22-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer